Neuralstem, Inc. (NASDAQ:CUR) announced its earnings results on Tuesday, August 8th. The company reported ($0.39) EPS for the quarter, beating analysts’ consensus estimates of ($9.49) by $9.10, Bloomberg Earnings reports. Neuralstem had a negative return on equity of 321.78% and a negative net margin of 198,573.91%.

Neuralstem (NASDAQ:CUR) traded up 1.72% during midday trading on Friday, hitting $1.18. The stock had a trading volume of 89,753 shares. The stock has a 50-day moving average price of $3.34 and a 200 day moving average price of $4.33. The firm’s market cap is $14.30 million. Neuralstem has a 12-month low of $0.22 and a 12-month high of $6.60.

Separately, ValuEngine cut Neuralstem from a “hold” rating to a “sell” rating in a report on Tuesday, July 25th.

ILLEGAL ACTIVITY NOTICE: “Neuralstem, Inc. (NASDAQ:CUR) Announces Quarterly Earnings Results” was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this story on another website, it was stolen and reposted in violation of U.S. & international copyright legislation. The legal version of this story can be viewed at https://www.thecerbatgem.com/2017/08/19/neuralstem-inc-nasdaqcur-posts-quarterly-earnings-results-beats-expectations-by-9-10-eps-updated.html.

About Neuralstem

Neuralstem, Inc (Neuralstem) is a clinical-stage biopharmaceutical company. The Company is engaged in research, development and commercialization of central nervous system therapies based on its human neuronal stem cells and its stem-cell derived small molecule compounds. The Company has approximately three assets: its NSI-189 small molecule program, its NSI-566 stem cell therapy program and its chemical entity screening platform.

Earnings History for Neuralstem (NASDAQ:CUR)

Receive News & Stock Ratings for Neuralstem Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuralstem Inc. and related stocks with our FREE daily email newsletter.